Medpace (MEDP) Projected to Release Earnings on Wednesday

Key Points

• Medpace is expected to report Q3 2026 results after the market closes on October 21. Analysts forecast $4.44 in earnings per share and $714.47 million in revenue; the earnings call is scheduled for October 22.
• The company exceeded expectations in its most recent quarter, posting $4.25 EPS versus the $3.98 consensus and $707.33 million in revenue, up 17.2% year over year.
• Analyst sentiment is mixed, with a consensus “Hold” rating and a $607.73 price target. Medpace shares recently traded near $610, while insiders sold more than $208 million of stock during the past quarter.

Medpace (NASDAQ:MEDP - Get Free Report) will likely be issuing its Q3 2026 results after the market closes on Wednesday, October 21st. Analysts expect Medpace to post earnings of $4.44 per share and revenue of $714.47 million for the quarter. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Individuals may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 22, 2026 at 9:00 AM ET.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%. The company's quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.10 EPS. On average, analysts expect Medpace to post $17.54 EPS for the current fiscal year and $19.17 EPS for the next fiscal year.

Medpace Stock Performance

NASDAQ MEDP opened at $609.89 on Wednesday. The business's 50 day moving average price is $604.41 and its 200-day moving average price is $529.15. Medpace has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The company has a market cap of $17.02 billion, a P/E ratio of 36.35, a P/E/G ratio of 2.77 and a beta of 1.18.

Insider Activity at Medpace

In other news, CEO August Troendle sold 49,018 shares of the company's stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the transaction, the chief executive officer owned 433,372 shares of the company's stock, valued at approximately $272,205,286.92. This represents a 10.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 336,140 shares of company stock worth $208,008,328 over the last quarter. Corporate insiders own 20.50% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on MEDP. UBS Group initiated coverage on shares of Medpace in a research note on Wednesday, September 30th. They set a "neutral" rating and a $673.00 price objective for the company. Barclays boosted their price objective on shares of Medpace from $600.00 to $625.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 7th. Mizuho increased their target price on shares of Medpace from $665.00 to $700.00 and gave the company an "outperform" rating in a research note on Wednesday, October 7th. Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. Based on data from MarketBeat, Medpace currently has an average rating of "Hold" and a consensus target price of $607.73.

Medpace Company Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.